Syngene International’s net sales for the quarter ending in March 2025 increased by 11.03%, reaching Rs 1,018 crore compared to the same quarter last year. However, despite the growth in sales, the operating profit margin declined slightly, from 34.56% to 33.75%, which led to an 8.43% increase in operating profit, amounting to Rs 343.6 crore.
Key Financial Changes:
- Raw material costs rose as a percentage of total sales, going from 19.42% to 22.56%.
- Employee costs decreased slightly, from 25.60% to 25.02%.
- Other expenses also saw a decrease, falling from 19.22% to 18.44%.
- Other income grew by 17.39%, reaching Rs 18.9 crore.
- Loan funds increased to Rs 577.9 crore, up from Rs 555.2 crore last year.
- Inventories dropped from Rs 238.5 crore to Rs 155.5 crore.
- Cash and bank balance rose significantly from Rs 563.5 crore to Rs 787 crore.
However, net profit decreased by 2.81%, dropping to Rs 183.3 crore. The effective tax rate also went up from 9.76% to 23.78%.
Full Year Results for 2024-2025
Syngene’s full-year revenue grew by 4.41%, reaching Rs 3,642.4 crore. Despite the rise in revenue, the operating profit margin dropped slightly from 29.08% to 28.60%.
- Employee costs rose from 25.89% to 27.14% of sales.
- Other income decreased by 20.75%, falling to Rs 71.8 crore.
- Net profit for the year also saw a decrease of 2.71%, reaching Rs 496.2 crore.
- Cash flow from operations improved, increasing to Rs 1,167.6 crore from Rs 1,042.1 crore the previous year.
- Fixed assets grew to Rs 4,037.5 crore, up from Rs 3,658.6 crore.
Business Highlights
Syngene’s board recommended a final dividend of Rs 1.25 per share for the year. The company also acquired a biologics manufacturing site in Baltimore, USA, which increased its capacity for biologics development and manufacturing. This acquisition strengthens Syngene’s position in the growing biologics sector, especially in the US.
Management’s Comments:
Peter Bains, Managing Director and CEO of Syngene, stated that the company had a solid performance, crossing Rs 1,000 crore in a quarter for the first time. He highlighted that the acquisition of the biologics facility in the US would further boost Syngene’s position in the industry. He added that Syngene expects good revenue growth in the coming year, despite global uncertainties, with growth likely coming from both small and large molecule programs.
Also See: Rallis India Tanks 4.53% After Q4 Shocker—Are Farmers or Investors Feeling the Heat More?
Deepak Jain, the company’s CFO, noted that the company’s growth was broad-based across its services, and the operating margins were maintained despite rising costs. He also mentioned that Syngene had a strong financial position and expects the momentum to continue into the next financial year. However, the addition of new facilities will increase costs and may impact profit margins.
Conclusion:
While Syngene’s revenue and sales growth are promising, it faced some challenges with rising costs and a decrease in net profit. However, with strong investments and strategic acquisitions, the company is well-positioned to grow further in the future.
